What neuroreparative value does Fosgonimeton Peptide possess?

In the field of drug development for neurodegenerative diseases, traditional symptomatic treatment strategies have long dominated, but they cannot stop the continuous loss of neurons and the disruption of synaptic connections. The emergence of Fosgonimeton Peptide offers a completely new therapeutic approach to this dilemma—it does not mimic neurotransmitters or clear amyloid plaques, but rather activates endogenous neurotrophic pathways by enhancing the binding of hepatocyte growth factor to its receptor MET. The HGF/MET signaling pathway regulates neuronal survival, synaptic plasticity, and neurogenesis in the central nervous system, and its function is significantly impaired in the brains of Alzheimer's disease patients.

🧬 Phosphate modification for a uniquely stable peptide chain conformation

Fosgonimeton Peptide is an Ang IV homologous modified short peptide with a complete peptide chain and phosphorylated phenyl side chains. The amino acid sequence features alternating hydrophilic and hydrophobic arrangements. The molecule relies on intramolecular hydrogen bonds formed between the phosphate groups on the side chains and the amide bonds in the peptide chain, folding into a fixed and compact three-dimensional conformation. Strict control of levorotatory chirality purity is maintained throughout the synthesis process, preventing the formation of racemic stereoisomers and fundamentally avoiding interference from isomeric molecules in neuronal detection indicators. Ordinary unmodified short peptides have a loose spatial structure and are rapidly hydrolyzed and broken down upon contact with brain tissue proteases, resulting in a very limited effective duration. This peptide, however, possesses a phosphate-modified protective group, allowing it to maintain its intact peptide backbone for extended periods under light-protected, lyophilized conditions at 2-8°C. Even during continuous incubation of hippocampal neurons and brain tissue slice culture for over ten days, its molecular activity did not show significant attenuation.

The hydrophobic amino acid cluster in the mid-segment of the peptide chain is a key functional region for binding to the MET receptor on the neuronal membrane surface. It can precisely embed into the receptor's specific hydrophobic pocket, relying on intermolecular hydrophobic interactions to stably adhere to the receptor structure, continuously amplifying the binding efficiency of HGF ligands to MET and upregulating downstream survival signal transduction. If this hydrophobic functional segment is deleted, the peptide cannot stably anchor to the target receptor, producing only a transient and weak pathway activation effect, making it unsuitable for long-term passage culture systems of aging nerve cells. The intact hydrophobic segment is the core foundation for the peptide to achieve neurotrophic regulation.

The phosphorylated phenyl side chain at the peptide chain's end is responsible for balancing the lipid-water partition ratio. The phosphate group significantly enhances the peptide's dispersion ability in aqueous culture media, preventing aggregation and precipitation during gradient dilution of incubation solutions. It also enhances the molecular lipid solubility, helping the peptide smoothly penetrate the vascular endothelial barrier and the phospholipid layer of the neuronal cell membrane, rapidly reaching the target region within brain tissue. Completely hydrophilic, unphosphate-modified short peptides cannot cross the blood-brain barrier, while strongly hydrophobic peptides without hydrophilic ends are difficult to dissolve uniformly. Fosgonimeton Peptide balances water solubility and central penetration efficiency, making it suitable for high-throughput neuron screening and large-scale simultaneous three-dimensional brain organoid culture.

The entire peptide lacks broad-spectrum protein binding ability, recognizing only MET receptors expressed on the surface of nerve cells. It does not stably bind to other growth factor receptors on peripheral somatic cells and immune cells, precisely distinguishing target proteins from conventional cellular proteins and significantly reducing interference from irrelevant pathways in the observation system. Arbitrarily removing side-chain phosphate modification groups directly reduces the peptide's penetration efficiency across the blood-brain barrier, significantly decreasing the effective concentration in brain tissue and consequently weakening its neurorepairing effect against the HGF/MET pathway.

⚙️ Mechanism of action of HGF/MET multi-pathway neurorepair

In healthy, young brain tissue, neurons and glial cells continuously express MET receptors. Endogenous HGF stably binds to these receptors, initiating downstream ERK and AKT survival signals, continuously promoting dendritic extension and synapse formation. Mitochondrial energy metabolism is stable, Aβ and hyperphosphorylated tau protein levels remain extremely low, the release of brain inflammatory factors is weak, synaptic plasticity related to learning and memory remains intact, and intracellular protein translation and ion metabolism processes are unaffected by exogenous peptides. Neuronal proliferation and differentiation maintain natural homeostasis.

When the brain undergoes aging and degeneration, Aβ amyloid protein deposition, dopamine neuron damage, or chronic neuroinflammation, the expression level of MET receptors in brain tissue continuously declines, endogenous HGF signaling is blocked, downstream survival pathway activity is significantly reduced, neuronal dendrites atrophy, synapses are lost in large quantities, mitochondria produce reactive oxygen species, and tau protein is abnormally hyperphosphorylated, forming neuronal tangles. Simultaneously, a large number of pro-inflammatory factors are released, gradually inducing neuronal apoptosis and cognitive memory decline. Conventional single antioxidant and synapse-promoting ingredients can only alleviate local surface damage and cannot repair damaged endogenous neurotrophic signaling pathways, leading to persistent and recurring brain pathological damage.

Fosgonimeton Peptide, after crossing the blood-brain barrier to reach neural tissue, anchors to the extracellular binding site of the MET receptor in its hydrophobic core segment, forming a positive allosteric regulatory effect. This enhances the binding affinity of HGF to the receptor, continuously activating downstream ERK and AKT survival-promoting signals, simultaneously inhibiting GSK3β kinase activity, and reducing abnormal phosphorylation of tau protein, thus blocking the source of neurotangle formation upstream. The peptide also simultaneously upregulates the expression of autophagy-related proteins, accelerating the degradation and clearance of intracellular Aβ amyloid debris and reducing the toxic damage of amyloid protein to neurons; at the same time, it downregulates the release of TNF-α and IL-1β pro-inflammatory factors from microglia, alleviating persistent low-grade inflammation in the brain. This triple-layered, simultaneous repair of neural damage distinguishes it from ordinary neuroprotective ingredients that only intervene in a single damage product.

The peptides exert their regulatory effects solely on the HGF/MET-mediated neurotrophic pathway specific to nerve cells, without interfering with other cell proliferation and transport structures such as epidermal growth factor and angiogenesis factor, and without disrupting the basal metabolic cycle of peripheral somatic cells. While broad-spectrum neurotrophic substances indiscriminately activate multiple growth factor pathways throughout the body, and observation systems are contaminated with numerous irrelevant cell proliferation interference signals, Fosgonimeton Peptide has a specific and clear target. Related observation systems can fix the single variable of "positive regulation of the HGF/MET pathway," improving the accuracy of observational conclusions related to cognitive decline and neurodegenerative damage.

🧫 Multi-faceted scientific research applications of peptides

Fosgonimeton Peptide is a standard control material for observing neuronal cell damage related to Alzheimer's disease, primarily used in the construction of primary hippocampal neurons and three-dimensional brain organoid Aβ injury models. Amyloid deposition in the aging brain continuously suppresses HGF/MET pathway activity. Leveraging its specific positive receptor activation properties, this product can be used for quantitative synaptic density fluorescence, tau protein phosphorylation detection, and electrophysiological recordings related to cellular memory. It enables the establishment of a standardized assessment system for cognitive-enhancing active substances, allowing for comparative analysis of the neuroplasticity repair capabilities of various centrally targeted peptides and small molecule modulators.

This material is widely used for neuropharmacological observation of Parkinson's disease-related dopaminergic neuronal damage and is suitable for co-culture models of 6-OHDA-induced dopaminergic neurons. Midbrain dopamine neuron degeneration synchronously downregulates MET receptor expression. Fosgonimeton Peptide can amplify endogenous HGF signaling, reduce the proportion of dopamine cell apoptosis, elucidate the nutritional compensation patterns after dopamine neuron degeneration, screen for active substances that delay motor nerve injury, and improve the screening platform for neuroprotective lead molecules for Parkinson's disease.

It has irreplaceable value in the observation of age-related cognitive impairment and traumatic brain injury mechanisms, and is used for the construction of in vitro models of aging cortical neurons and traumatic stress-induced neuronal cells. Long-term brain aging and traumatic brain injury synchronously inhibit neurotrophic pathways and induce oxidative inflammation chain reactions. This product can simultaneously repair synaptic structures, clear pathological proteins, and alleviate glial inflammation. It is widely used in the exploration of Alzheimer's disease and post-traumatic brain injury sequelae, expanding the research and development direction of neuroprotective peptides targeting the HGF/MET pathway.

The development of novel central nervous system nutritional active molecules globally uniformly uses Fosgonimeton Peptide as the efficacy reference benchmark. Various modified short peptides, blood-brain barrier-targeting derivatives, and long-acting neuromodulatory peptides require cross-sectional comparisons of core indicators such as MET receptor activation efficiency, synaptic regeneration enhancement, pathological protein clearance capacity, and peripheral somatic cell non-specific proliferative toxicity. Stable and uniform pathway positive activation activity, extremely low off-target interference, and reproducible neural cell observation data make it a universal reference standard for high-throughput screening of neuropeptides, structure-activity relationship analysis of short peptides, and iterative optimization of molecular structures.

🔬 Molecular optimization development direction

Site-specific modification of the phosphophenyl side chain at the peptide terminus is currently the mainstream approach for optimizing Fosgonimeton Peptide, with modification sites concentrated in the phosphorylated aromatic residue region. While the original peptide diffuses uniformly throughout the body, its concentration in hippocampal and midbrain lesions is limited, requiring moderate concentrations to achieve pathway activation. By grafting a cerebral endothelial-specific affinity short peptide onto the phosphophenyl terminus, the modified derivative can be directionally enriched in the neurological regions of brain lesions, amplifying HGF/MET signaling at lower molar doses, reducing trace peptide exposure in peripheral somatic cells, and adapting to the construction of low-dose, long-acting brain neurorepair models.

Microenvironment-responsive modification in neurodegenerative lesions is another mainstream optimization route, mitigating the weak basal cellular metabolic interference caused by indiscriminate peptide diffusion. By inserting a masking group that can be cleaved by highly active proteases in aging and damaged regions onto the phosphophenyl side chain, lesion-specific activating peptides can be constructed. The modified peptides exhibit no MET receptor activation activity in healthy neurons, thus not interfering with basal cell growth and metabolism. Only after entering Aβ-deposited, dopamine-damaged neurons, the masking groups are enzymatically cleaved, releasing the active Fosgonimeton core peptide. This precisely regulates target pathways, further enhancing molecular specificity and aligning with the trend towards low-toxicity, targeted neuroprotective peptide optimization.

Multifunctional hybrid peptide splicing broadens the boundaries of action, overcoming the functional limitations of single HGF pathway regulation. Long-term neurodegenerative damage is often accompanied by multiple problems such as microvascular degeneration and autophagy imbalance; simply amplifying neurotrophic signals cannot completely repair brain tissue damage. By covalently splicing the Fosgonimeton core short peptide with vascular repair and strong antioxidant short peptides, a multifunctional fusion peptide is created. This peptide simultaneously achieves the triple effects of activating MET receptors, degrading amyloid protein, and scavenging intracellular reactive oxygen species, overcoming the shortcomings of single-target neurorepair raw materials and providing a new approach for the design of complex anti-dementia lead peptides.

The amino acid substitution in the hydrophobic functional region of the peptide chain finely adjusts the receptor binding strength, adapting to the personalized needs of different neurological observation scenarios. The original Fosgonimeton Peptide exhibits balanced activation intensity of MET receptors in hippocampal and midbrain neurons, making it suitable for general aging cognitive models. By substituting the types of hydrophobic residues, rapid-acting and mild, long-acting sustained-release derivatives can be prepared. The high-acting version is suitable for short-term intervention observation of acute traumatic brain injury, while the sustained-release version is suitable for long-term passaging models of Alzheimer's neurons, enabling precise observation of neurotrophic pathway regulation based on genotyping.

Conclusion

Fosgonimeton Peptide relies on a phosphate-modified hydrophilic-hydrophobic alternating short peptide stable folding backbone. It amplifies endogenous HGF neurotrophic signals by positively allosterically activating neuronal MET receptors, simultaneously promoting synaptic regeneration, degrading brain pathological proteins, inhibiting neuroinflammation and oxidative damage, and repairing neuronal degeneration induced by aging, amyloid protein, and dopamine deficiency. It can be used to build an in vitro neuronal model of Alzheimer's cognitive decline, as well as to observe Parkinson's neurological injury and traumatic brain protection mechanisms, spanning three major fields: cognitive neuropharmacology, degenerative brain disease protection, and central peptide delivery.

Xi'an Faithful BioTech is your trusted supplier of Fosgonimeton Peptide. We provide pharmaceutical-grade products and ensure our production processes comply with GMP standards. Our experienced team of professionals can tailor solutions to your various business needs, including bulk purchase discounts, assistance with regulatory documentation, and flexible order handling for different sizes. Please contact allen@faithfulbio.com to discuss your needs and learn how our high-quality raw materials can support your product line growth.

References

1. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Positive Modulator of HGF/MET, Fosgonimeton, in Healthy Volunteers and Subjects with Alzheimer's Disease: Randomized, Placebo-Controlled, Double-Blind, Phase I Clinical Trial. Journal of Alzheimer's Disease. 2022;86(3):1399-1413.
2. Athira Pharma. (2022). ACT-AD: Fosgonimeton in mild-to-moderate Alzheimer's disease – first results of a randomized, placebo-controlled, 26-week Phase 2 proof-of-concept trial. Alzheimer's & Dementia.
3. ClinicalTrials.gov. (2025). A Randomized, Placebo-Controlled, Double-Blind Study of ATH-1017 Treatment in Subjects With Parkinson's Disease Dementia or Dementia With Lewy Bodies (SHAPE Trial). NCT04831281.
4. ClinicalTrials.gov. (2025). ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease (LIFT-AD). NCT04488419.
5. Therapeutic Target Database. (n.d.). Fosgonimeton (ATH-1017). TTD Drug Information.